MOLOGEN signs license deal for China and global co-development agreement with ONCOLOGIE for lead compound lefitolimod
• MOLOGEN to receive a EUR 3 million initial payment as well as a EUR 2 million equity investment • Milestone payments of above EUR 100 million and double digit royalties on net sales • Strong support for global development program of lefitolimod,…